Outcomes and Prognostic Factors in Patients with Hematologic Malignancies in the Intensive Care unit: A Single-Center Cohort Study of 233 Cases in Taiwan

Chieh-Lung Chen
CMUH: China Medical University Hospital  https://orcid.org/0000-0003-1340-746X

Sing-Ting Wang
CMUH: China Medical University Hospital

Wen-Chien Cheng
CMUH: China Medical University Hospital

Chih-Yu Chen
CMUH: China Medical University Hospital

Wei-Cheng Chen
CMUH: China Medical University Hospital

Yu-Chao Lin
CMUH: China Medical University Hospital

Biing-Ru Wu
CMUH: China Medical University Hospital

Wei-Chih Liao (weichih.liao@gmail.com)
China Medical University Hospital,  https://orcid.org/0000-0002-2539-5323

Research

Keywords: hematologic malignancies, intensive care unit, Sequential Organ Failure Assessment score

DOI: https://doi.org/10.21203/rs.3.rs-152665/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Patients with a hematologic malignancies (HM) have one of the highest mortality rates among cancer patients admitted to the medical intensive care unit (ICU). The aim of this study was to identify outcomes and risk factors that predict the prognosis of critically ill patients with HM in the ICU.

Methods

A retrospective observational study was conducted in a tertiary referral hospital in Taiwan over 40 months (January 1, 2017–April 30, 2020). All adult patients with HM who were admitted to medical ICU were enrolled. Clinical data upon hospital and ICU admission were collected. The predictors of ICU mortality were evaluated using a multivariate analysis.

Results

A total of 233 patients with HM met the inclusion criteria. The median age (SD) was 59.3 (15.1) years, and 76% of the HMs were classified as high-grade disease. The median (IQR) Sequential Organ Failure Assessment (SOFA) score at ICU admission was 11 (9–15); Simplified Acute Physiology Score II, 64 (51–80); and Acute Physiology and Chronic Health Evaluation II score, 28 (23–34). The most common reasons for ICU admission were acute respiratory failure (63.1%) and septic shock (19.7%). The ICU and hospital mortality rates were 54.1% and 67.8%, respectively. A multivariate analysis revealed that the initiation of renal replacement therapy in the ICU (odds ratio [OR], 3.88; 95% CI, 1.66–9.08) and SOFA score (OR, 1.16; 95% CI, 1.03–1.31) were independently associated with ICU mortality.

Conclusions

The ICU and hospital outcomes of critically ill patients with HM are improving. Performance status, cancer status, invasive mechanical ventilation, severe neutropenia, and transplantation status were not identified as predictive factors of ICU outcome. Initiation of renal replacement therapy in the ICU and the SOFA score upon ICU admission were independently associated with ICU mortality. We suggest early and timely ICU admission of patients at risk of multiorgan failure.

Background

Cancer survival has been steadily improving over the last few decades, and more patients have been admitted to the intensive care unit (ICU) for the management of critical illnesses related either directly or indirectly to cancer (1). Compared with other patients with cancer who are admitted to the ICU, patients with hematologic malignancies (HMs) are generally more ill and have a higher mortality rate (2, 3). Recent advances in diagnosis, chemotherapy and conditioning regimes, innovative treatment regimens and targeted therapies, and general ICU care have led to better outcomes in these patients (4–6). As a result, physicians are now less reluctant to admit hematologic patients to the ICU than in the 1990s (7, 8).
Previous studies identified several indicators of poor prognosis, including older age (9), neutropenia (10–12), disease progression (13), allogeneic hematopoietic stem cell transplantation (HSCT) (14, 15), graft versus host disease (GVHD) (16), high Sequential Organ Failure Assessment (SOFA) score (17), high Simplified Acute Physiology Score (SAPS) II (12, 18, 19), high Acute Physiology and Chronic Health Evaluation (APACHE) II score (9, 10, 12, 20), invasive mechanical ventilation (10, 15, 17, 21), renal replacement therapy (19, 20), hepatic dysfunction (18, 20), and invasive fungal infection (14). However, the prognostic significance of some variables has changed in the last few years, and published studies have yielded conflicting results (15, 22).

Few studies have been conducted for this patient group in the Asian population. With substantial improvement in supportive care and cancer treatment in recent years, we aimed to evaluate the outcome of patients with HM admitted to ICU in Taiwan and identify predictors of ICU mortality.

Methods

Patients and setting

This retrospective single-center observational study was conducted in a tertiary referral hospital in mid-Taiwan, which is a 1722-bed hospital with a 45-bed adult medical intensive care unit and 7-bed bone marrow transplantation facility. Approximately 80 HSCT procedures are performed annually in the hospital.

This study was approved by the institutional review board of China Medical University Hospital (CMUH109-REC3-137), and informed consent was waived because of the retrospective nature of the study and the data gathered did not include any personally identifiable information. Data were collected on all adult patients admitted to the ICU with HM as the primary diagnosis or a concurrent comorbidity over a 40-month period (January 1, 2017–April 30, 2020). The hospital information system and medical records were reviewed. Patients transferred from the respiratory care ward (RCW) and admitted to the ICU for surgical indications or postoperative monitoring were excluded from the study. If the patient was admitted to the ICU more than once in a 28-day period, the first admission was included (Fig. 1).

Data collection

The variables recorded were patient characteristics, performance status at hospital admission using the Eastern Cooperative Oncology Group scale, type of HM, disease status at the time of admissions, previous HSCT, presence of GVHD, severe neutropenia, reason for ICU admission, whether invasive mechanical ventilation was needed, and whether renal replacement therapy was initiated in the ICU. The severity of illness at ICU admission was assessed using the SOFA score, SAPS II, and APACHE II score. All the scores were calculated using the patient data collected at the time of ICU admission or within 24 hours of ICU admission.

Definitions
HMs were categorized as follows: acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphoblastic leukemia (CLL), chronic myeloid leukemia (CML), Hodgkin’s lymphoma (HL), aggressive non-Hodgkin’s lymphoma (NHL), indolent NHL, and multiple myeloma (MM). AML, ALL, and aggressive non-Hodgkin’s lymphoma were classified as high grade diseases.

Disease status was defined as complete remission (CR), partial remission (PR), stable disease (SD), and relapsed or refractory disease. In patients with newly diagnosed HM without treatment or unexpected hospital admission prior to the assessment of tumor response to cancer therapeutics, disease status was labeled as “non-evaluable.”

Statistical Analyses

Statistical analyses were completed using SPSS version 25 (SPSS Inc., Chicago, IL, USA). The normality of all the variables was studied using the Kolmogorov-Smirnov test. Data are expressed as mean with standard deviations or median and interquartile range (IQR) for variables with and without a normal distribution, respectively. Continuous data with normal distributions were analyzed using a t test. For ordinal data and data that are not normally distributed, differences between groups were assessed using a Mann-Whitney U test. The categorical variables were presented as numbers and percentages and analyzed using the chi-square test. A univariate analysis was used to calculate the odds ratio (OR) of mortality, and the statistically significant variables were used in the multivariate logistic regression model analysis. The strength of association was presented as OR and 95% confidence interval (CI). All the tests were two-sided, and a p value of < 0.05 was considered to indicate a statistically significant difference.

Results

During the study period, 4521 patients were admitted to the medical ICU and 1194 patients (26.4%) had an underlying or current diagnosis of any type of malignancy, including 252 patients with HM. After excluding patients admitted for surgical indications, postoperative monitoring, RCW cases, and readmission to the ICU in a 28-day period, 233 patients, representing 5.2% of all ICU admissions, were evaluated.

Patient characteristics

The patients’ mean (SD) age was 59.2 years (15.1), and 39.5% of the patients were female (Table 1). Of the patients, 25.8% (60) had a performance status of 0–2 at hospital admission; 42.1%, 3; and 32.2%, 4. All the patients had a confirmed HM based on pathological examination results or medical records, including 46% with leukemia, 41% with lymphoma; and 13% with plasma cell dysplasia (Fig. 2). Seventy-six percent of the HMs were classified as high-grade disease. Twenty-four percent of the patients received allogeneic HSCT, and 4.7% underwent autogenic HSCT, of which 14.2% had GVHD. A total of 81 patients (34.8%) had a relapsed or refractory disease. Notably, 31 patients (13.3%) had a newly diagnosed HM in the ICU.
The median (IQR) time in hospital before ICU admission was 5 days (0–24 days). Nearly 30% of patients were admitted to the ICU directly from the emergency department. The most frequent reasons for ICU admission were acute respiratory failure (63.1%) and septic shock (19.7%). Most patients (88.8%) required invasive mechanical ventilation, and 32.2% of the patient had initiation of renal replacement therapy in the ICU. The median durations of ICU and hospital stays were 8 days (IQR: 3–16 days, range: 1–51 days) and 27 days (IQR: 15–52 days, range: 1–168 days), respectively.

The illness severity scores were calculated at the time of ICU admission or within 24 hours of admission to the ICU for each case. The median (IQR) SOFA score was 11 (9–15); SAPS II score, 64 (51–80); and APACHE II score, 28 (23–34) (Table 2).

Outcomes

The ICU and hospital mortality rates were 54.1% and 67.8%, respectively. Although the overall mortality remained high, the ICU mortality rate decreased during the years of observation (Fig. 2), but the difference was not statistically significant.

Poor performance status, high-grade HM, relapsed or refractory disease, increased time in hospital before ICU admission, initiation of renal replacement therapy in the ICU, and high SOFA, SAPS II, and APACHE II scores were associated with ICU mortality (Table 3). When all of the above-mentioned variables were included, only the initiation of renal replacement therapy in the ICU (OR, 3.88; 95% CI, 1.66–9.08) and SOFA scores (OR, 1.16; 95% CI, 1.03–1.31) were independently associated with ICU mortality (Table 4). The area under the receiver-operating characteristic (ROC) curve to predict ICU mortality was 0.81 (95% CI, 0.75–0.87) when the two variables were used in one model (Table 2).

Discussion

This study is one of the largest single-center studies of ICU patients with HM and includes a considerable proportion of patients with HSCT. To the best of our knowledge, this is the first study in Taiwan to report the prognostic factor related to short-term outcomes in critically ill patients with HM.

The ICU and hospital mortalities in our study were 54.1% and 67.8%, respectively. A recent single-center study from Germany reported ICU mortalities rates of 45.2% (in 2009–2012 cohort) and 66.7% (in 2013–2016 cohort) at different time periods (23). To a wider extent, the previously published ICU and hospital mortality rates in patients with HM who were admitted to the ICU ranged from 24.8–66% and from 43–77%, respectively (15). The differences in mortality observed between studies including ours may be
explained by variations in disease severity, admission and discharge criteria, treatment decisions, and the implementation of end-of-life decisions. Notably, the disease severity at ICU admission was higher in our patient than those reported in previous studies. With persisting high overall mortality, the ICU mortality decreased during the years of observation (Fig. 3), which may be attributable to better supportive care, improved management of sepsis (24), and acute respiratory distress syndrome (ARDS) (25). Although this finding was not statistically significant, the trend of decreased ICU mortality was consistent with previous studies (4–6).

Several prognostic factors for critically ill patients with HM were published by previous studies, and some were considered “classical” risk factors. Neutropenia, poor performance status, advanced cancer status, invasive mechanical ventilation, vasopressors, renal replacement therapy, HSCT, and increasing time in hospital before ICU admission have been shown to be useful predictors of ICU and hospital mortality rates in previous studies. Scoring systems such as the APACHE II and SAPS II were widely validated in previous studies. However, in our study, only the initiation of renal replacement therapy in the ICU and SOFA scores were independently associated with ICU mortality. The area under the ROC curve to predict ICU mortality increased to 0.81 (95% CI, 0.75–0.87) when the two variables were combined. This result was consistent with previous results that the presence of organ failure was the major factor of poor outcome (10, 14, 17, 20, 22, 26). In previous studies, the SOFA score was less validated in predicting the ICU outcome of critically ill patients with HM than the APACHE II and SAPS II. However, the SOFA scoring system is a less cumbersome tool in clinical practice and had been applied in determining the duration of time-limited trials of intensive care for critically ill patients with cancer (27). Our result encourages clinicians to use the SOFA score for triage decisions and time-limited trial in the patient group.

Early ICU admission of patients identified as being at risk of multiorgan failure had been recommended (4), and early intervention before ICU admission in critically ill cancer patients was proved to decrease in-hospital mortality (28). In our study, 68 patients (29.2%) were admitted to the ICU directly from the emergency department, of whom 49 survived the ICU stay. Time in hospital before ICU admission was significantly higher in the non-survivor group. Although we could not clarify the relationship between time in hospital before ICU admission and delayed ICU admission, our data supports the concept that early and timely admission to the ICU in patient identified as high risk of severe organ dysfunction (29). Thus, underlying HM disease, neutropenia, and even post HSCT status should not be considered as a reason for delayed endotracheal tube intubation or ICU admission.

Thirty-one patients (13.3%) had pathologically confirmed HMs in the ICU, and in 15 patients, administration of antineoplastic agents was initiated as a first-line treatment in the ICU. Of all the patients, 11 survived the ICU stay and 6 were still alive 180 days after ICU discharge. It is crucial that a hematologic specialist is involved in the ICU management (30). With the emergence of novel agents for treating HMs, specific therapies under the recommendation of a hematologic specialist may lead to improved outcome and long-term survival (31).
This study has several limitations. First, this was a retrospective single-center study. However, it analyzed data collected over 40 months from one of the largest medical centers in Taiwan and enrolled a considerable number of patients. Second, the mortality rate was higher in our patients than in those in previous studies (15). However, the severity index was higher in our patients, and the crude mortality was difficult to compare from those in other studies because of the variations in admission and discharge criteria. Third, we could not demonstrate the impact of time-limited trials, which was a widely known concept in the management of critically ill patients with cancer (27). The decision of whether to treat these patients in the ICU remains difficult and needs evaluation on a patient-to-patient basis. A recent multicenter retrospective cohort study with 1097 patients in the Netherlands suggested that even in multiorgan failure, it should not be used as a criterion for excluding patients with HMAs from admission to the ICU (8).

Future studies should focus on ICU-acquired infections in this patient group; further clarifying the relationship between time in hospital before ICU admission and delayed ICU admission; long-term outcomes after ICU discharge, including quality of life; and new epidemiology and challenges in ICU admission in the era of immunotherapy.

**Conclusion**

With the persistently high overall mortality, a trend of decreasing ICU mortality was observed in our study, which may be attributable to the improved general ICU care. Risk factors, including poor performance status, advanced cancer status, mechanical ventilation, severe neutropenia, transplantation status, and GVHD, and the widely used risk scores, including SAPS II score and APACHE II, were not predictive of ICU outcome. Initiation of renal replacement therapy in the ICU and the SOFA score upon ICU admission were independently associated with ICU mortality. We suggest early and timely ICU admission of patients identified as at risk of multiorgan failure.

**Abbreviations**
| Abbreviation | Definition |
|--------------|------------|
| ALL          | Acute lymphoblastic leukemia |
| AML          | Acute myeloid leukemia |
| APACHE       | Acute Physiology and Chronic Health Evaluation |
| ARDS         | Acute respiratory distress syndrome |
| CI           | Confidence interval |
| CLL          | Chronic lymphoblastic leukemia |
| CML          | Chronic myeloid leukemia |
| CR           | Complete remission |
| ECOG         | Eastern Cooperative Oncology Group |
| GVHD         | Graft Versus Host Disease |
| HL           | Hodgkin's lymphoma |
| HM           | Hematologic malignancy |
| HSCT         | Hematopoietic stem cell transplantation |
| ICU          | Intensive care unit |
| IQR          | Interquartile range |
| MM           | Multiple myeloma |
| MV           | Mechanical ventilation |
| NHL          | Non-Hodgkin's lymphoma |
| OR           | Odds ratio |
| PR           | Partial remission |
| RCW          | Respiratory care ward |
| ROC          | Receiver operating characteristic |
| RRT          | Renal replacement therapy |
| SAPS II      | Simplified Acute Physiology Score II |
| SD           | Stable disease, Standard deviation |
| SOFA         | Sequential Organ Failure Assessment |

**Declarations**
Ethics approval and consent to participate

This study was approved by the Institutional Review Board of China Medical University Hospital (CMUH109-REC3-137), and informed consent was waived because of the retrospective nature of the study and the data gathered did not include any personally identifiable information.

Consent for publication

Not applicable

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests

Funding

None.

Authors’ contributions

BRW and WCL designed the study and were guarantor of the paper. CLC and STW were involved in clinical data collection and arrangement. WCC and CYC helped with data analysis and interpretation of the results. CLC and STW prepared the draft and finalized the manuscript. WCC and YCL also reviewed the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

Author details

1 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan

2 Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan

3 Center for Hyperbaric Oxygenation Therapy, China Medical University Hospital, Taichung, Taiwan

4 School of Medicine, China Medical University, Taichung, Taiwan
References

1. van Vliet M, Verburg IW, van den Boogaard M, de Keizer NF, Peek N, Blijlevens NM, et al. Trends in admission prevalence, illness severity and survival of haematological patients treated in Dutch intensive care units. Intensive Care Med. 2014;40(9):1275–84.

2. Taccone FS, Artigas AA, Sprung CL, Moreno R, Sakr Y, Vincent JL. Characteristics and outcomes of cancer patients in European ICUs. Crit Care. 2009;13(1):R15.

3. Oeyen SG, Benoit DD, Annemans L, Depuydt PO, Van Belle SJ, Troisi RI, et al. Long-term outcomes and quality of life in critically ill patients with hematological or solid malignancies: a single center study. Intensive Care Med. 2013;39(5):889–98.

4. Azoulay E, Mokart D, Pene F, Lambert J, Kouatchet A, Mayaux J, et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium—a groupe de recherche respiratoire en reanimation onco-hematologique study. J Clin Oncol. 2013;31(22):2810–8.

5. Pulte D, Jansen L, Castro FA, Brenner H. Changes in the survival of older patients with hematologic malignancies in the early 21st century. Cancer. 2016;122(13):2031–40.

6. Azoulay E, Pene F, Darmon M, Lengline E, Benoit D, Soares M, et al. Managing critically ill hematology patients: Time to think differently. Blood Rev. 2015;29(6):359–67.

7. Brunet F, Lanore JJ, Dhainaut JF, Dreyfus F, Vaxelaire JF, Nouira S, et al. Is intensive care justified for patients with haematological malignancies? Intensive Care Med. 1990;16(5):291–7.

8. de Vries VA, Muller MCA, Arbous MS, Biemond BJ, Blijlevens NMA, Kusadasi N, et al. Long-Term Outcome of Patients With a Hematologic Malignancy and Multiple Organ Failure Admitted at the Intensive Care. Crit Care Med. 2019;47(2):e120-e8.

9. Hampshire PA, Welch CA, McCrossan LA, Francis K, Harrison DA. Admission factors associated with hospital mortality in patients with haematological malignancy admitted to UK adult, general critical care units: a secondary analysis of the ICNARC Case Mix Programme Database. Crit Care. 2009;13(4):R137.

10. Lloyd-Thomas AR, Wright I, Lister TA, Hinds CJ. Prognosis of patients receiving intensive care for lifethreatening medical complications of haematological malignancy. Br Med J (Clin Res Ed). 1988;296(6628):1025–9.

11. Benoit DD, Vandewoude KH, Decruyenaere JM, Hoste EA, Colardyn FA. Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complication. Crit Care Med. 2003;31(1):104–12.

12. Owczuk R, Wujtewicz MA, Sawicka W, Wadrzyk A, Wujtewicz M. Patients with haematological malignancies requiring invasive mechanical ventilation: differences between survivors and non-survivors in intensive care unit. Support Care Cancer. 2005;13(5):332–8.

13. Yau E, Rohatiner AZ, Lister TA, Hinds CJ. Long term prognosis and quality of life following intensive care for life-threatening complications of haematological malignancy. Br J Cancer. 1991;64(5):938–
Massion PB, Dive AM, Doyen C, Bulpa P, Jamart J, Bosly A, et al. Prognosis of hematologic malignancies does not predict intensive care unit mortality. Crit Care Med. 2002;30(10):2260–70.

Al-Zubaidi N, Shehada E, Alshabani K, Zaza Dit Yafawi J, Kingah P, Soubani AO. Predictors of outcome in patients with hematologic malignancies admitted to the intensive care unit. Hematol Oncol Stem Cell Ther. 2018;11(4):206–18.

Huaringa AJ, Leyva FJ, Giralt SA, Blanco J, Signes-Costa J, Velarde H, et al. Outcome of bone marrow transplantation patients requiring mechanical ventilation. Crit Care Med. 2000;28(4):1014–7.

Lamia B, Hellot MF, Girault C, Tamion F, Dachraoui F, Lenain P, et al. Changes in severity and organ failure scores as prognostic factors in onco-hematological malignancy patients admitted to the ICU. Intensive Care Med. 2006;32(10):1560–8.

Gordon AC, Oakervee HE, Kaya B, Thomas JM, Barnett MJ, Rohatiner AZ, et al. Incidence and outcome of critical illness amongst hospitalised patients with haematological malignancy: a prospective observational study of ward and intensive care unit based care. Anaesthesia. 2005;60(4):340–7.

Kroschinsky F, Weise M, Illmer T, Haenel M, Bornhaeuser M, Hoeffken G, et al. Outcome and prognostic features of intensive care unit treatment in patients with hematological malignancies. Intensive Care Med. 2002;28(9):1294–300.

Evison J, Rickenbacher P, Ritz R, Gratwohl A, Haberthur C, Elsasser S, et al. Intensive care unit admission in patients with haematological disease: incidence, outcome and prognostic factors. Swiss Med Wkly. 2001;131(47–48):681–6.

Staudinger T, Stoiser B, Mullner M, Locker GJ, Laczika K, Knapp S, et al. Outcome and prognostic factors in critically ill cancer patients admitted to the intensive care unit. Crit Care Med. 2000;28(5):1322–8.

Bird GT, Farquhar-Smith P, Wigmore T, Potter M, Gruber PC. Outcomes and prognostic factors in patients with haematological malignancy admitted to a specialist cancer intensive care unit: a 5 year study. Br J Anaesth. 2012;108(3):452–9.

Kondakci M, Reinbach MC, Germing U, Kobbe G, Fenk R, Schroeder T, et al. Interaction of increasing ICU survival and admittance policies in patients with hematologic neoplasms: A single center experience with 304 patients. Eur J Haematol. 2019;102(3):265–74.

Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304–77.

Acute Respiratory Distress. Syndrome N, Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301–8.

Geerse DA, Span LF, Pinto-Sietsma SJ, van Mook WN. Prognosis of patients with haematological malignancies admitted to the intensive care unit: Sequential Organ Failure Assessment (SOFA) trend
is a powerful predictor of mortality. Eur J Intern Med. 2011;22(1):57–61.

27. Shrim MG, Ferket BS, Scott DJ, Lee J, Barragan-Bradford D, Pollard T, et al. Time-Limited Trials of Intensive Care for Critically Ill Patients With Cancer: How Long Is Long Enough? JAMA Oncol. 2016;2(1):76–83.

28. Song JU, Suh GY, Park HY, Lim SY, Han SG, Kang YR, et al. Early intervention on the outcomes in critically ill cancer patients admitted to intensive care units. Intensive Care Med. 2012;38(9):1505–13.

29. Mokart D, Lambert J, Schnell D, Fouche L, Rabbat A, Kouatchet A, et al. Delayed intensive care unit admission is associated with increased mortality in patients with cancer with acute respiratory failure. Leuk Lymphoma. 2013;54(8):1724–9.

30. Azoulay E, Recher C, Alberti C, Soufir L, Leleu G, Le Gall JR, et al. Changing use of intensive care for hematological patients: the example of multiple myeloma. Intensive Care Med. 1999;25(12):1395–401.

31. Xia R, Wang D. Intensive care unit prognostic factors in critically ill patients with advanced solid tumors: a 3-year retrospective study. BMC Cancer. 2016;16:188.

**Tables**

**Table 1** Patient characteristics
|                           |       |
|---------------------------|-------|
| **N=233**                 |       |
| Age (years)               | 59.2 ± 15.1 |
| Female                    | 92 (39.5%) |
| Body weight               | 60.5 ± 11.5 |
| ECOG Performance Status at admission |       |
| 0                         | 2 (0.9%) |
| 1                         | 15 (6.4%) |
| 2                         | 43 (18.5%) |
| 3                         | 98 (42.1%) |
| 4                         | 75 (32.2%) |
| Cancer type               |       |
| Leukemia                  | 108 (46.4%) |
| Lymphoma                  | 95 (40.8%) |
| Plasma cell dysplasia     | 30 (12.9%) |
| High grade hematological malignancies | 177 (76%) |
| Hematopoietic stem cell transplantation |       |
| Allogeneic                | 56 (24%) |
| Autogenic                 | 11 (4.7%) |
| Graft versus host disease | 33 (14.2%) |
| Cancer status             |       |
| Complete remission (CR)   | 34 (14.6%) |
| Partial remission (PR)    | 14 (6%) |
| Stable disease (SD)       | 11 (4.7%) |
| Relapsed or refractory    | 81 (34.8%) |
| Non-evaluable             | 93 (39.9%) |
| Newly diagnosed malignancy| 75 (32.2%) |
| Cancer diagnosed in ICU   | 31 (13.3%) |
Admitted to ICU directly from Emergency room 68 (29.2%)
Time in hospital before ICU admission (day) 5 (0-24)
Main reason for ICU admission
   Acute respiratory failure 147 (63.1%)
   Septic shock 46 (19.7%)
   Cardiac arrest 15 (6.4%)
ICU intervention
   Invasive mechanical ventilation 207 (88.8%)
   Initiation of renal replacement therapy 75 (32.2%)
   ECMO 6 (2.6%)
   Antineoplastic treatment in ICU 54 (23.2%)

**Abbreviations**: ECOG = Eastern Cooperative Oncology Group; ICU = Intensive care unit; ECMO = Extracorporeal membrane oxygenation

### Table 2 Severity of illness scores upon admission to the ICU

| Severity of illness score | Score | Area under the (ROC) curve to predict ICU mortality |
|---------------------------|-------|----------------------------------------------------|
| SOFA score at ICU admission | 11 (9-15) | 0.769 |
| SAPS II at ICU admission | 64 (51-80) | 0.768 |
| APACHE II at ICU admission | 28 (23-34) | 0.721 |
| SOFA score + initiation of hemodialysis in ICU | - | 0.809 |

**Abbreviations**: ICU = Intensive care unit; ROC = Receiver operating characteristic; SOFA = Sequential Organ Failure Assessment; SAPS = Simplified Acute Physiology Score; APACHE = Acute Physiology and Chronic Health Evaluation

### Table 3 Comparisons between ICU survivors and non-survivors with hematological malignancies
| Characteristics                                      | Survivors (N=107) | Non-survivors (N=126) | p value |
|------------------------------------------------------|-------------------|-----------------------|---------|
| **Age**                                              | 59.4 ± 15.4       | 59.0 ± 14.9           | 0.832   |
| **Female**                                          | 44 (41.1%)        | 48 (38.1%)            | 0.638   |
| **Body mass index**                                  | 22.7 ± 4.0        | 22.5 ± 3.4            | 0.742   |
| **ECOG Performance Status at admission**             |                   |                       | <0.001  |
| 0-2                                                  | 24 (22.4%)        | 36 (28.6%)            |         |
| 3#                                                   | 32 (29.9%)        | 66 (52.4%)            |         |
| 4#                                                   | 51 (47.7%)        | 24 (19.0%)            |         |
| **Newly diagnosed malignancy**                       | 31 (29%)          | 44 (34.9%)            | 0.333   |
| **High grade hematological malignancies**           | 69 (64.5%)        | 108 (85.7%)           | <0.001  |
| **Cancer status**                                    |                   |                       | 0.022   |
| Non-progressive (CR, PR, SD) a                      | 35 (32.7%)        | 24 (19.0%)            |         |
| Relapsed or refractory a                             | 29 (27.1%)        | 52 (41.3%)            |         |
| Non-evaluable                                        | 43 (40.2%)        | 50 (39.7%)            |         |
| **HSCT**                                             |                   |                       | 0.699   |
| No                                                   | 79 (73.8%)        | 87 (69.0%)            |         |
| Allogeneic                                           | 23 (21.5%)        | 33 (26.2%)            |         |
| Autogeneric                                          | 5 (4.7%)          | 6 (4.8%)              |         |
| **GVHD**                                             | 13 (12.1%)        | 20 (15.9%)            | 0.417   |
| **Duration of neutropenia b (day)**                  | 7 (3-24)          | 9 (2.25-23.75)c       | 0.889   |
| **CRP at ICU admission (mg/dL)**                     | 20.96 (8.19-30.49)| 18.57 (6.02-29.3)     | 0.07    |
| **Albumin at ICU admission (g/dL)**                  | 2.7 (2.2-3.8)     | 2.9 (2.53-3.1)        | <0.001  |
| **Time in hospital before ICU admission (day)**      | 0 (0-19)          | 23 (2.25-42.25)       | <0.001  |
| **Respiratory support at ICU admission**             |                   |                       | 0.046   |
| Oxygen support a                                     | 11 (10.3%)        | 4 (3.2%)              |         |
| NIV                                                  | 3 (2.8%)          | 8 (6.3%)              |         |
| MV                                                   | 93 (86.9%)        | 114 (90.5%)           |         |
Table 4 Univariate analysis and multivariate logistic regression analysis of the prognostic variables for ICU mortality

(a) The adjusted standardized residual was greater than 2 which indicates the column proportions were significantly different at p<0.05 level

(b) Severe neutropenia was defined as absolute neutrophil count (ANC) < 500/uL

(c) Duration of neutropenia was underestimated in 44.3% patients (N=51) with severe neutropenia (N=115)

(d) Fisher’s exact test

Abbreviations: ECOG = Eastern Cooperative Oncology Group; ICU = Intensive care unit; CR = Complete remission; PR = Partial remission; SD = Stable disease; PD = disease progression; HSCT = Hematopoietic stem cell transplantation; GVHD = Graft versus host disease; NIV = Non-invasive ventilation; MV = Mechanical ventilation; RRT = Renal replacement therapy; ECMO = Extracorporeal membrane oxygenation; CRP = C-Reactive protein; PCT = Procalcitonin; SOFA = Sequential Organ Failure Assessment; SAPS = Simplified Acute Physiology Score; APACHE = Acute Physiology and Chronic Health Evaluation
### Variables

| Variables                             | Univariate analysis with logistic regression analysis | Multivariate analysis with logistic regression analysis |
|---------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                       | OR        | 95% CI     | p value | OR        | 95% CI     | p value |
| --------------------------------------|-----------|-------------|----------|-----------|-------------|----------|
| **ECOG Performance Status at admission** |           |             |          |           |             |          |
| 0-2                                   | 1         |             |          | 1         |             |          |
| 3                                     | 1.38      | 0.71-2.68   | 0.349    | 2.01      | 0.80-5.09   | 0.139    |
| 4                                     | 0.31      | 0.15-0.64   | **0.001**| 0.54      | 0.19-1.59   | 0.265    |
| High grade hematological malignancies | 3.30      | 1.75-6.25   | **<0.001**| 2.31      | 0.95-5.62   | 0.065    |
| **Cancer status**                     |           |             |          |           |             |          |
| Non-progressive (CR, PR, SD)          | 1         |             |          | 1         |             |          |
| Relapsed or refractory                | 2.62      | 1.31-5.21   | **0.006**| 1.60      | 0.61-4.18   | 0.336    |
| Non-evaluable                         | 1.70      | 0.88-3.28   | 0.117    | 0.80      | 0.31-2.03   | 0.634    |
| **Albumin at ICU admission (g/dL)**   | 0.34      | 0.21-0.56   | **<0.001**| 0.54      | 0.29-1.03   | 0.059    |
| **Time in hospital before ICU admission (day)** | 1.01    | 1.00-1.03   | **0.021**| 1.01      | 0.99-1.02   | 0.509    |
| **Respiratory support at ICU admission** |          |             |          |           |             |          |
| Oxygen support                        | 1         |             |          | 1         |             |          |
| NIV                                   | 7.33      | 1.27-42.29  | **0.026**| 4.29      | 0.36-50.75  | 0.249    |
| MV                                    | 3.37      | 1.04-10.93  | **0.043**| 1.55      | 0.32-7.40   | 0.584    |
| Initiation of RRT in ICU              | 7.00      | 3.56-13.79  | **<0.001**| 3.88      | 1.66-9.08   | **0.002**|
| SOFA score at ICU admission           | 1.33      | 1.21-1.45   | **<0.001**| 1.16      | 1.03-1.31   | **0.017**|
| SAPS II at ICU admission              | 1.06      | 1.04-1.08   | **<0.001**| 1.04      | 1.00-1.08   | 0.059    |
| APACHE II at ICU admission            | 1.12      | 1.07-1.16   | **<0.001**| 0.97      | 0.89-1.06   | 0.471    |

**Abbreviations:** ECOG = Eastern Cooperative Oncology Group; ICU = Intensive care unit; CR = Complete remission; PR = Partial remission; SD = Stable disease; PD = disease progression; NIV = Non-invasive ventilation; MV = Mechanical ventilation; RRT = Renal replacement therapy; SOFA = Sequential Organ Failure Assessment; SAPS = Simplified Acute Physiology Score; APACHE = Acute Physiology and Chronic Health Evaluation
Figures

Figure 1

Study design and flow chart
Figure 2

Patterns of hematologic malignancies of the study population Non-Hodgkin’s lymphoma, acute myeloid leukemia, and acute lymphoblastic leukemia comprising the most prevalent types of malignancy. Seventy-six percent of the hematologic malignancies were classified as high-grade disease (3). Abbreviations: ALL = Acute lymphoblastic leukemia; AML = Acute myeloid leukemia; CLL = Chronic lymphoblastic leukemia; CML = Chronic myeloid leukemia
There was a decrease in ICU mortality during the years of observation; but it was not statistically significant.

Figure 3

ICU and hospital mortality rate. There was a decrease in ICU mortality during the years of observation; but it was not statistically significant.